Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Histological changes in different proliferation, apoptosis and autophagy markers.
To determine whether topical application of Calcitriol (Silkis) 3 μg/g, Diclofenac 3% or a combination of both can lead to a 40% histological reduction (↓)/increase (↑) of expression of the following antibodies: Ki67 (↓), BCL2 (↓), CASPASE 3 (↑) and Cox2 (↓) (proliferation and apoptosis), LC3B (↑) (autophagy), HIF1α (↓) (hypoxia), β-catenin (↓), sFRP4 (↑) and sFRP5 (↑) (Wnt pathway activity).
At baseline and after 8 weeks.
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)